Acute Lymphoblastic Leukemia Clinical Trials

A listing of 78 Acute Lymphoblastic Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Acute Lymphoblastic Leukemia

1 - 12 of 78

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 78 active clinical trials seeking participants for Acute Lymphoblastic Leukemia research studies. The states with the highest number of trials for Autism participants are California, Illinois, Michigan and Ohio.

Featured Trial

Major Depressive Disorder Clinical Study

Recruiting

Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.

Conditions:

Major Depressive Disorder

Major Depression

Major Depressive Episode

Major Depressive Disorder (MDD)

Major Depressive Disorders

Learn More

Featured Trial

Hyperacusis Activities Treatment-Online Study

Recruiting

Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.

Conditions:

Hyperacusis

Tinnitus

Hearing Loss

Learn More

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845

Recruiting

The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).

Gender:

All

Ages:

18 years and above

Trial Updated:

08/28/2023

Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

Conditions: Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia

Learn More ›

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

NCT03960840

Recruiting

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: University Of California LA UCLA Hematology Oncology, Los Angeles, California +39 locations

University Of California LA UCLA Hematology Oncology, Los Angeles, California

Stanford University Medical Center, Stanford, California

H Lee Moffitt Cancer Center and Research Institute ., Tampa, Florida

Northside Hospital ., Atlanta, Georgia

Northwestern University Northwestern Memorial Hospital Trans, Chicago, Illinois

Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois

University of Kansas Cancer Center SC - CTL019C2201, Westwood, Kansas

Mass Gen Hosp Cancer Center ., Boston, Massachusetts

Montefiore Medical Center ., Bronx, New York

University of Pennsylvania Clinical Perelman Center for Adv Med, Philadelphia, Pennsylvania

Sarah Cannon Research Institute Drug Ship - 4, Nashville, Tennessee

Sarah Cannon Research Institute Methodist Hospital, Nashville, Tennessee

St Davids South Austin Medical Ctr, Austin, Texas

Uni of TX MD Anderson Cancer Cntr, Houston, Texas

Medical College of Wisconsin Main Centre, Milwaukee, Wisconsin

Novartis Investigative Site, Melbourne, Victoria

Novartis Investigative Site, Wien, Not set

Novartis Investigative Site, Marseille, Not set

Novartis Investigative Site, Paris 10, Not set

Novartis Investigative Site, Pierre Benite, Not set

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Frankfurt, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Bergamo, BG

Novartis Investigative Site, Bologna, BO

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Rozzano, MI

Novartis Investigative Site, Fukuoka city, Fukuoka

Novartis Investigative Site, Sapporo city, Hokkaido

Novartis Investigative Site, Bunkyo ku, Tokyo

Novartis Investigative Site, Cordoba, Andalucia

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Salamanca, Castilla Y Leon

Novartis Investigative Site, Badalona, Catalunya

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Valencia, Comunidad Valenciana

Novartis Investigative Site, Barcelona, Not set

Novartis Investigative Site, Madrid, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

Learn More ›

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

NCT05800210

Recruiting

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMA... Read More

Gender:

All

Ages:

Between 6 months and 39 years

Trial Updated:

05/02/2024

Locations: University of Florida, Gainesville, Florida

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin

Learn More ›

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

NCT05621291

Recruiting

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it can be hard to achieve remission again. In patients where CART fails, stem cell transplant (HCT) can be used to prevent relapse and achieve cure. But HCT can cause serious side effects. Better testing i... Read More

Gender:

All

Ages:

Between 1 year and 25 years

Trial Updated:

05/02/2024

Locations: Children's Hospital of Los Angeles, Los Angeles, California +7 locations

Conditions: B-All, Acute Lymphoblastic Leukemia

Learn More ›

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

NCT03263572

Recruiting

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate and cyt... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)

Learn More ›

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

NCT04537871

Recruiting

This study evaluates how well the heart, lungs, and muscles are working individually, and how these systems are working together in transplant survivors. Information collected in this study may help doctors to understand why hematopoietic stem cell transplant survivors are at higher risk for developing cardiovascular disease.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/01/2024

Locations: City of Hope Medical Center, Duarte, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma

Learn More ›

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

NCT06195891

Recruiting

This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS). Total marrow and lymphoid irradiation is a targeted form of total body irradiation that uses intensity-modulated radiation therapy to target marrow, lymph node chains, and t... Read More

Gender:

All

Ages:

All

Trial Updated:

04/30/2024

Locations: City of Hope Medical Center, Duarte, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias

NCT05969002

Recruiting

Background Acute lymphoblastic leukemia (ALL) accounts for about 25% of childhood cancers and for about 20% of adult leukemias. The disease can be treated with CAR T-cell infusion but non-central nervous system (CNS) extramedullary disease (EMD) is associated with lower rates of complete remission. 18-fludeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) has been shown to be effective for detection of non-CNS EMD in ALL. Pre and post CAR T-cell infusion may help to... Read More

Gender:

All

Ages:

Between 5 years and 39 years

Trial Updated:

04/24/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: B Cell, Acute Lymphoblastic Leukemia, Relapsed/Refractory

Learn More ›

A Study of JNJ-75276617 in Participants With Acute Leukemia

NCT04811560

Recruiting

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion).

Gender:

All

Ages:

12 years and above

Trial Updated:

04/23/2024

Locations: City of Hope, Duarte, California +23 locations

Conditions: Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia

Learn More ›

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

NCT03564678

Recruiting

This phase II trial studies how well levocarnitine and vitamin B complex works in treating abnormal high liver enzyme levels (hyperbilirubinemia) caused by treatment with PEG-asparaginase or inotuzumab ozogamicin in patients with acute lymphoblastic leukemia. Amino acids, such as levocarnitine, may work in normalizing liver enzyme levels due to treatment. Vitamin B complex is a dietary supplement that may be used for patients with nutritional deficiencies. Giving levocarnitine and vitamin B comp... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/22/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Hyperbilirubinemia

Learn More ›

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT03016377

Recruiting

The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been sufficient to cure most patients. This study combines both T cells and antibodies to try to create a more effective treatment. This investigational treatment is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD19 antigen (ATLCAR.CD19) administration. In previous studies, it has been shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying the genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells makes a piece of an antibody called anti-CD19. This antibody can flow through the blood and can find and stick to leukemia cells because these leukemia cells have a substance on their surface called CD19. Anti-CD19 antibodies have been used to treat people with leukemia but have not been strong enough to cure most patients. For this study, the anti-CD19 antibody has been changed so that instead of floating free in the blood a piece of it is now joined to the surface of the T cells. Only the part of the antibody that sticks to the leukemia cells is attached to the T cells instead of the entire antibody. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD19 chimeric (combination) receptor-activated T cells kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. Preliminary results of giving ATLCAR.CD19 cells to leukemia patients have been encouraging; however, many subjects receiving this treatment have experienced unwanted side effects including neurotoxicity and/or cytokine release syndrome (also referred to as cytokine storm or an infusion reaction). Cytokines are small proteins that interreact as e signals to other cells and are the way cells talk to one another. During cytokine release syndrome, too many cytokines are released and too many cells in your body react to their release. Symptoms resulting from cytokine release syndrome vary from flu-like symptoms to more severe side effects such as cardiac arrest, multi-system organ failure or death. We predict that about 50% of patients on this study will experience mild to severe cytokine release syndrome. To help reduce cytokine release syndrome symptoms in future patients, a safety switch has been added to the ATLCAR.CD19 cells that can cause the cells to become dormant or "go to sleep". The safety switch is called inducible caspase 9 or iC9. The modified ATLCAR.CD19 cells with the safety switch are referred to as iC9-CAR19 cells. The purpose of this study is to determine whether receiving the iC9-CAR19 cells is safe and tolerable (there are not too many unwanted effects). Researchers has previously tested different doses of the iC9-CAR19. An effective dose that had the least number of unwanted side effects in patients was identified. It was planned to test this dose in more patients to learn more about its effect in the body. This type of research study is called a dose expansion study. It will allow the investigators to collect more information about the effect of this dose in treating of certain type of cancer. Read Less

Gender:

All

Ages:

Between 3 years and 70 years

Trial Updated:

04/19/2024

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

Conditions: Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders

Learn More ›

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

NCT04726241

Recruiting

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Gender:

All

Ages:

22 years and below

Trial Updated:

04/18/2024

Locations: Children's Hospital of Alabama, Birmingham, Alabama +168 locations

Children's Hospital of Alabama, Birmingham, Alabama

USA Health Strada Patient Care Center, Mobile, Alabama

Providence Alaska Medical Center, Anchorage, Alaska

Banner Children's at Desert, Mesa, Arizona

Phoenix Childrens Hospital, Phoenix, Arizona

Banner University Medical Center - Tucson, Tucson, Arizona

Arkansas Children's Hospital, Little Rock, Arkansas

Kaiser Permanente Downey Medical Center, Downey, California

Loma Linda University Medical Center, Loma Linda, California

Miller Children's and Women's Hospital Long Beach, Long Beach, California

Children's Hospital Los Angeles, Los Angeles, California

Valley Children's Hospital, Madera, California

UCSF Benioff Children's Hospital Oakland, Oakland, California

Kaiser Permanente-Oakland, Oakland, California

Children's Hospital of Orange County, Orange, California

Lucile Packard Children's Hospital Stanford University, Palo Alto, California

Rady Children's Hospital - San Diego, San Diego, California

UCSF Medical Center-Mission Bay, San Francisco, California

Children's Hospital Colorado, Aurora, Colorado

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado

Connecticut Children's Medical Center, Hartford, Connecticut

Yale University, New Haven, Connecticut

Alfred I duPont Hospital for Children, Wilmington, Delaware

Children's National Medical Center, Washington, District of Columbia

Broward Health Medical Center, Fort Lauderdale, Florida

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Nicklaus Children's Hospital, Miami, Florida

Nemours Children's Hospital, Orlando, Florida

Sacred Heart Hospital, Pensacola, Florida

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida

Saint Mary's Hospital, West Palm Beach, Florida

Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia

Memorial Health University Medical Center, Savannah, Georgia

Kapiolani Medical Center for Women and Children, Honolulu, Hawaii

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Lurie Children's Hospital-Chicago, Chicago, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Loyola University Medical Center, Maywood, Illinois

Saint Jude Midwest Affiliate, Peoria, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Riley Hospital for Children, Indianapolis, Indiana

Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana

Blank Children's Hospital, Des Moines, Iowa

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Norton Children's Hospital, Louisville, Kentucky

Children's Hospital New Orleans, New Orleans, Louisiana

Ochsner Medical Center Jefferson, New Orleans, Louisiana

Maine Children's Cancer Program, Scarborough, Maine

Sinai Hospital of Baltimore, Baltimore, Maryland

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Walter Reed National Military Medical Center, Bethesda, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

C S Mott Children's Hospital, Ann Arbor, Michigan

Children's Hospital of Michigan, Detroit, Michigan

Michigan State University Clinical Center, East Lansing, Michigan

Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

Beaumont Children's Hospital-Royal Oak, Royal Oak, Michigan

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota

Mayo Clinic in Rochester, Rochester, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

Columbia Regional, Columbia, Missouri

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Cardinal Glennon Children's Medical Center, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Mercy Hospital Saint Louis, Saint Louis, Missouri

Children's Hospital and Medical Center of Omaha, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada

Summerlin Hospital Medical Center, Las Vegas, Nevada

Renown Regional Medical Center, Reno, Nevada

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Medical Center, Morristown, New Jersey

Saint Peter's University Hospital, New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey

Saint Joseph's Regional Medical Center, Paterson, New Jersey

Albany Medical Center, Albany, New York

Montefiore Medical Center - Moses Campus, Bronx, New York

Maimonides Medical Center, Brooklyn, New York

NYU Winthrop Hospital, Mineola, New York

The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

University of Rochester, Rochester, New York

Stony Brook University Medical Center, Stony Brook, New York

State University of New York Upstate Medical University, Syracuse, New York

New York Medical College, Valhalla, New York

Mission Hospital, Asheville, North Carolina

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

East Carolina University, Greenville, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Sanford Broadway Medical Center, Fargo, North Dakota

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Rainbow Babies and Childrens Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Dayton Children's Hospital, Dayton, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Legacy Emanuel Children's Hospital, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania

Geisinger Medical Center, Danville, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Medical University of South Carolina, Charleston, South Carolina

Prisma Health Richland Hospital, Columbia, South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

East Tennessee Childrens Hospital, Knoxville, Tennessee

Saint Jude Children's Research Hospital, Memphis, Tennessee

The Children's Hospital at TriStar Centennial, Nashville, Tennessee

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

Dell Children's Medical Center of Central Texas, Austin, Texas

Driscoll Children's Hospital, Corpus Christi, Texas

Medical City Dallas Hospital, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

El Paso Children's Hospital, El Paso, Texas

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

M D Anderson Cancer Center, Houston, Texas

Covenant Children's Hospital, Lubbock, Texas

UMC Cancer Center / UMC Health System, Lubbock, Texas

Children's Hospital of San Antonio, San Antonio, Texas

Methodist Children's Hospital of South Texas, San Antonio, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Primary Children's Hospital, Salt Lake City, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

Inova Fairfax Hospital, Falls Church, Virginia

Children's Hospital of The King's Daughters, Norfolk, Virginia

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

Carilion Children's, Roanoke, Virginia

Seattle Children's Hospital, Seattle, Washington

Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington

Mary Bridge Children's Hospital and Health Center, Tacoma, Washington

Madigan Army Medical Center, Tacoma, Washington

West Virginia University Healthcare, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

The Children's Hospital at Westmead, Westmead, New South Wales

Queensland Children's Hospital, South Brisbane, Queensland

Royal Children's Hospital, Parkville, Victoria

Perth Children's Hospital, Perth, Western Australia

Alberta Children's Hospital, Calgary, Alberta

University of Alberta Hospital, Edmonton, Alberta

British Columbia Children's Hospital, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

IWK Health Centre, Halifax, Nova Scotia

Children's Hospital, London, Ontario

Children's Hospital of Eastern Ontario, Ottawa, Ontario

Hospital for Sick Children, Toronto, Ontario

The Montreal Children's Hospital of the MUHC, Montreal, Quebec

Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec

CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Not set

Starship Children's Hospital, Grafton, Auckland

Christchurch Hospital, Christchurch, Not set

HIMA San Pablo Oncologic Hospital, Caguas, Not set

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome

Learn More ›

1 - 12 of 78